BR0312347A - Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato - Google Patents

Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato

Info

Publication number
BR0312347A
BR0312347A BR0312347-2A BR0312347A BR0312347A BR 0312347 A BR0312347 A BR 0312347A BR 0312347 A BR0312347 A BR 0312347A BR 0312347 A BR0312347 A BR 0312347A
Authority
BR
Brazil
Prior art keywords
coating material
coating
polymethacrylate
active compound
dissolving
Prior art date
Application number
BR0312347-2A
Other languages
English (en)
Inventor
Christopher J Speirs
Peter Moir
Richard Williams
Michael Clark
Original Assignee
Temrel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30117101&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0215656A external-priority patent/GB0215656D0/en
Priority claimed from GB0215657A external-priority patent/GB0215657D0/en
Application filed by Temrel Inc filed Critical Temrel Inc
Publication of BR0312347A publication Critical patent/BR0312347A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ORAL, E, USOS DA ESPESSURA DE REVESTIMENTO DE UM MATERIAL DE REVESTIMENTO DEPENDENTE DO PH DE DISSOLUçãO, DE UM MATERIAL DE REVESTIMENTO, E DE UM MATERIAL DE POLIMETACRILATO". Uma composição melhorada para o controle do perfil de liberação de um composto ativo ao longo do trato intestinal é composta de partículas, especialmente de grânulos, contendo o composto ativo, que são revestidos com um material de revestimento dependente do pH de dissolução ou um material de polimetacrilato, o qual de preferência, é dependente do pH de dissolução, até uma certa espessura, dependente do local e da taxa de liberação do componente ativo que é desejado. Em composições preferidas, dois ou mais conjuntos de partículas, nos quais cada conjunto é revestido com um material de revestimento dependente do pH de dissolução ou de um material de polimetacrilato até uma espessura diferente daquela de cada um dos outros conjuntos, são contidos dentro de uma cápsula revestida entericamente e produzem a liberação do composto ativo em vários locais desejados no trato intestinal.
BR0312347-2A 2002-07-05 2003-07-04 Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato BR0312347A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215656A GB0215656D0 (en) 2002-07-05 2002-07-05 Controlled release composition
GB0215657A GB0215657D0 (en) 2002-07-05 2002-07-05 Controlled release composition for the treatment of inflammatory bowel disease
PCT/GB2003/002911 WO2004004696A1 (en) 2002-07-05 2003-07-04 Controlled release composition

Publications (1)

Publication Number Publication Date
BR0312347A true BR0312347A (pt) 2005-04-12

Family

ID=30117101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312347-2A BR0312347A (pt) 2002-07-05 2003-07-04 Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato

Country Status (15)

Country Link
US (4) US20060127484A1 (pt)
EP (1) EP1519717B1 (pt)
JP (1) JP2005532387A (pt)
CN (1) CN1665490A (pt)
AT (1) ATE482694T1 (pt)
AU (1) AU2003244840C1 (pt)
BR (1) BR0312347A (pt)
CA (1) CA2491355A1 (pt)
DE (1) DE60334378D1 (pt)
DK (1) DK1519717T3 (pt)
MX (1) MXPA05000128A (pt)
NZ (1) NZ537632A (pt)
PL (1) PL374922A1 (pt)
RU (1) RU2336865C2 (pt)
WO (1) WO2004004696A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2005060938A1 (en) 2003-12-23 2005-07-07 Temrel Limited Process for producing pellets for pharmaceutical compositions
US9875508B1 (en) 2004-11-19 2018-01-23 Allstate Insurance Company Systems and methods for customizing insurance
US10282785B1 (en) 2004-11-19 2019-05-07 Allstate Insurance Company Delivery of customized insurance products and services
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
CA2838399C (en) * 2006-02-09 2017-03-07 Alba Therapeutics Corporation Formulations for a tight junction effector
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
EP2762132A1 (en) 2007-04-25 2014-08-06 Cytochroma Inc. Controlled Release 25-Hydroxyvitamin D
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
CN102238946B (zh) * 2008-11-07 2014-11-26 株式会社三养生物制药 用于哌醋甲酯的控制释放的药物组合物
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
ES2836811T3 (es) * 2010-01-15 2021-06-28 Kemin Ind Zhuhai Co Ltd Alfa-amilasa protegida
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
US20140065213A1 (en) * 2011-05-06 2014-03-06 GlaxoSmithKline, LLC Sustained Release Paracetamol Formulations
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
AU2012305915B2 (en) * 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
TWI747893B (zh) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素ｄ治療之方法
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF PROGRAMMED CELL DEATH LIGAND 1
WO2018112240A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3554539B9 (en) * 2016-12-14 2023-10-04 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR20190097107A (ko) 2016-12-14 2019-08-20 프로제너티, 인크. Jak 저해제로의 위장관 질환의 치료 및 장치
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
CN113929807B (zh) * 2021-06-25 2022-09-27 贵州省欣紫鸿药用辅料有限公司 一种烯烃酸树脂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
DE19724696A1 (de) 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ATE438418T1 (de) * 2001-05-01 2009-08-15 Av Topchiev Inst Petrochemical Hydrogel-zusammensetzungen

Also Published As

Publication number Publication date
AU2003244840C1 (en) 2010-03-04
DK1519717T3 (da) 2011-01-10
ATE482694T1 (de) 2010-10-15
RU2336865C2 (ru) 2008-10-27
US20130230588A1 (en) 2013-09-05
EP1519717A1 (en) 2005-04-06
RU2005102838A (ru) 2005-08-10
US20110182986A1 (en) 2011-07-28
MXPA05000128A (es) 2005-09-30
US20060127484A1 (en) 2006-06-15
US20140322317A1 (en) 2014-10-30
AU2003244840B2 (en) 2009-09-10
EP1519717B1 (en) 2010-09-29
PL374922A1 (en) 2005-11-14
WO2004004696A1 (en) 2004-01-15
AU2003244840A1 (en) 2004-01-23
JP2005532387A (ja) 2005-10-27
NZ537632A (en) 2006-06-30
CA2491355A1 (en) 2004-01-15
DE60334378D1 (de) 2010-11-11
CN1665490A (zh) 2005-09-07

Similar Documents

Publication Publication Date Title
BR0312347A (pt) Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato
DK1480624T3 (da) Farmaceutisk tablet
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
DE60103186D1 (de) Stossweise freisetzende Arzneiabgabesysteme
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
NO20016108D0 (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
RS52798B (en) PHARMACEUTICAL DOSAGE FORMS
MY148475A (en) Controlled release preparations comprising tramadol and topiramate
ME00482B (me) Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje
DE60321386D1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
EA200300110A1 (ru) Композиция элетриптана в виде частиц
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
ATE341312T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
DE60219965D1 (de) Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
CR6858A (es) Composiciones de eletriptan en forma de particulas que muestra el curso sigmoideo de liberacion controlada
FR2890862B1 (fr) Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
WO2007062262A3 (en) Gelatinous medicament formulation and method of administration

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2313 DE 05/05/2015